Sick days due to depression up 50% among German workers, report finds
The mental health report by DAK-Gesundheit, released on Sunday, said there were 183 sick days due to depression for every 100 employees the company insured in 2024, up from 122 days in the previous year.
Sick days due to mental health rose from 323 to 342 per 100 employees, the figures showed, with workers in child care and elderly care work particularly affected.
"The high number of mental illnesses is often associated with long absences and stigmatization for the affected employees and their employers," said DAK chief executive Andreas Storm. "We can no longer close our eyes, because mental health is a key success factor for a resilient society and for Germany as a strong business location."
Storm called for increased awareness of the causes and taboo-free information on depression and anxiety disorders as well as support services to strengthen mental health.
All age groups are affected by the rise in depression. The figures for younger people have been gradually increasing for several years, while there was a sharp rise in the older age groups in 2024.
According to the DAK figures, the average duration of sick leave due to mental illness in 2024 was just under 33 days, slightly above the previous year's level.
DAK-Gesundheit is one of the largest statutory health insurance companies in Germany.
The mental health report was conducted using the anonymized data of 2.42 million DAK-insured employees, with the help of the IGES Institute in Berlin.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11-07-2025
- Yahoo
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial
Penumbra, Inc. (NYSE:PEN) is one of the The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial has enrolled 100 patients in order to evaluate computer assisted vacuum thrombectomy (CAVT) through utilising Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for treating acute intermediate-high risk pulmonary embolism (PE). An operating theatre showcasing medical solutions from the company. In the US, an estimated 900,000 cases of symptomatic PE take place annually. Pulmonary embolism could be life-threatening, with 10% – 30% of individuals dying within 1 month of diagnosis. Penumbra, Inc. (NYSE:PEN)'s Lightning Flash portfolio happens to be the most advanced mechanical thrombectomy system on the market, focused on addressing venous and pulmonary thrombus. Penumbra, Inc. (NYSE:PEN)'s gross profit for Q1 2025 came in at $215.9 million, or 66.6% of total revenue, compared to $181.1 million, or 65.0% of total revenue, for Q1 2024. This improvement in gross margin was mainly because of favorable product mix throughout the regions and productivity improvements. Penumbra, Inc. (NYSE:PEN) increased its guidance for the U.S. Thrombectomy franchise growth to 20% – 21% YoY from 19% – 20% previously. It reiterated the guidance for gross margin expansion of a minimum of 100 bps in 2025, to over 67% for FY 2025. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a position in Penumbra, Inc. (NYSE:PEN), a leading manufacturer of medical devices that remove blood clots from veins and arteries. Physicians use the company's devices to treat pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia, ischemic stroke, coronary disease, and other conditions. Penumbra's devices, which are called mechanical thrombectomy devices, use computer algorithms to modulate the aspiration power depending on if a clot is detected and to control a separate valve that injects saline to reduce friction between the clot and catheter. This enables a differentiated device profile that maximizes clot removal with speed while decreasing risk of blood loss. While we acknowledge the potential of PEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Wire
16-06-2025
- Business Wire
Quiver Bioscience Appoints Graham Dempsey, PhD as Chief Executive Officer to Lead Scaling of AI-Driven CNS Platform and Advance Lead Program into the Clinic
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quiver Bioscience ('Quiver'), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, announced the appointment of co-founder Graham Dempsey, PhD as Chief Executive Officer. Dr. Dempsey assumes the CEO role after more than a decade of scientific and operational leadership at Quiver, most recently serving as Quiver's Chief Scientific Officer, directing the planning and execution of all scientific, medical, engineering and AI/machine learning activities at the company. This appointment comes as Quiver aims to advance its lead program into the clinic, an antisense oligonucleotide (ASO) targeting Na v 1.7 for the treatment of chronic pain, while scaling its CNS-focused AI-driven drug discovery platform to accelerate a portfolio of therapeutic programs. Paul Roma, Quiver co-founder and interim CEO will transition to Chairman of the Board of Directors. 'We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain," said Dr. Dempsey Share Dr. Dempsey has successfully led the development and rapid evolution of the company's technology platforms since the company's inception, as well as its first small molecule and antisense oligonucleotide therapeutic programs, resulting in several foundational patents and peer-reviewed publications. He has also led more than a dozen pharma collaborations and the execution of several grants from non-dilutive funding sources such as the NIH SBIR Programs and CNS Foundations. Dr. Dempsey holds a B.A. in biochemistry (Roy and Diana Vagelos Scholar) and biophysics from the University of Pennsylvania and a Ph.D. in biophysics from Harvard Medical School, where he co-invented novel fluorescence-based imaging platforms for investigating biological systems and was part of the team that developed the super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM) that was subsequently commercialized by Nikon Instruments. Dr. Dempsey serves on the Scientific Advisory Board of the Dan Lewis Foundation for Brain Regeneration Research and the editorial board of Molecular Therapy Nucleic Acids. Under Dr. Dempsey's leadership, Quiver will advance their lead asset, an ASO targeting the genetically validated pain target Na v 1.7, a voltage gated sodium channel implicated in several neuropathic pain disorders, through IND and early clinical studies. 'Despite the longstanding promise of Nav1.7 as a target for pain, it has remained elusive for drug developers. We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain,' said Dr. Dempsey. Quiver's Na v 1.7 ASO is expected to deliver durable relief for chronic pain while overcoming limitations of other Na v -targeted small molecules currently under development and recently approved. Quiver's strong data package demonstrates the efficacy of Na v 1.7 ASOs in rescuing pain phenotypes in in vitro and in vivo models with a favorable CNS tolerability profile. The ASO program is approaching development candidate selection in 2025 and is expected to begin critical IND enabling studies shortly thereafter. Quiver is also scaling their human-centric AI-driven novel CNS drug discovery platform with in silico models of target, efficacy and toxicity prediction, and is further bolstering a pipeline of fast-follower programs in pain, neurodevelopmental disorders, and other diseases of the CNS including the advancement of its UBE3A -targeting ASO for the neurodevelopmental disorder, chromosome 15q duplication syndrome (Dup15q) to IND. The company will be attending the BIO International Convention in Boston this week to showcase their programs and platform. About Quiver Bioscience Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For more information, including partnerships and publications describing application of Quiver's GPS to drug discovery, visit or follow us on LinkedIn.
Yahoo
04-06-2025
- Yahoo
Greystone Expands FHA Lending Team with the Addition of Corley Audorff and Josh Williams
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Greystone, a leading national commercial real estate finance company, announced today that Corley Audorff and Josh Williams have joined the firm as Directors. Both based in Atlanta, GA, Mr. Audorff and Mr. Williams will focus on loan originations for multifamily and seniors housing / healthcare assets, reporting to Field Springer, Chief Operating Officer of Greystone's FHA Lending platform. Mr. Audorff brings over 15 years of experience in real estate finance, most recently serving as a Senior Vice President of Production at Colliers Mortgage from 2022 to 2025, where he focused on HUD/FHA, Fannie Mae, USDA and proprietary lending financing solutions for clients. Prior to his role at Colliers, Mr. Audorff served as a Vice President at PGIM Real Estate, where he specialized in HUD financing, and has also spent time as a Managing Director at Monticello Asset Management. Prior to his work in the private sector, Mr. Audorff served approximately seven years in various roles at the U.S. Department of Housing and Urban Development, including Senior Underwriter. Mr. Williams also joins from Colliers Mortgage, where he was a Vice President from 2022 to 2025. He previously served as a Senior Associate Loan Officer at PGIM Real Estate and as an Underwriter and Production Associate at Monticello Asset Management. His expertise spans multifamily and healthcare sectors, with a strong background in FHA-insured loan products. 'I'm thrilled to join Greystone, the #1 multifamily and healthcare HUD lender*, and work to continue our success together as a team, in multifamily and healthcare finance,' said Mr. Audorff. 'The company's depth of resources, integrated lending platform, and client-focused culture create an environment where I can contribute meaningfully to impactful transactions in the seniors housing and multifamily sectors.' 'Both Corley and Josh's combined depth of experience across the private and public sectors in multifamily and healthcare financing makes them an invaluable addition to our lending team,' said Mr. Springer. 'Together, they strengthen our reach and capabilities in key asset classes and geographies.' About Greystone Greystone Servicing Company is a private national commercial real estate finance company with an established reputation as a leader in multifamily and healthcare finance, having ranked as a top FHA, Fannie Mae, and Freddie Mac lender in volume for these sectors. Greystone loans are offered through Greystone Servicing Company LLC, Greystone Funding Company LLC and/or other Greystone affiliates. For more information, visit *For HUD's 2024 fiscal year. Based upon combined firm commitments of Greystone Funding Company LLC and Greystone Servicing Company LLC. PRESS CONTACT:Karen
